Skip to main content
Premium Trial:

Request an Annual Quote

Flatiron Health, FDA Partner on Cancer Research Project

NEW YORK (GenomeWeb) – Flatiron Health announced today that it has signed a research deal with the US Food and Drug Administration to determine how real-world evidence derived from patient data captured outside of clinical trials can provide insights into the safety and efficacy of new anti-cancer therapies.

"With only four percent of the adult US cancer population enrolled in clinical trials, we as providers are currently limited to making clinical decisions based upon study results that represent only a small number of patients," Flatiron Chief Medical Officer Amy Abernethy said in a statement. "This makes it nearly impossible to estimate whether a treatment will work, anticipate all of the potential side effects of therapies, or even decide which treatment should precede another." 

Under the terms of the deal, Flatiron and the FDA's Center for Drug Evaluation and Research will start by using de-identified, HIPPA-compliant data from patients with advanced non-small cell lung cancer who are receiving immunotherapy to explore analytic approaches, clinically relevant endpoints, and safety assessment methods.

"Collaborative projects such as this one with the FDA allow us to access real-world evidence for more accurate and actionable insights into patient care and expected outcomes outside of clinical trials, supporting the delivery of high quality patient care," Abernethy added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.